Skip to content

Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms.

Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms.

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05096468
Enrollment
90
Registered
2021-10-27
Start date
2021-12-01
Completion date
2022-10-15
Last updated
2023-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Postoperative Pain, Esketamine, Neurosurgical Procedures, Perioperative Complication, Pregabalin, Spinal Cord Neoplasms

Brief summary

Postsurgical pain is now known to be one of the most common and difficult-to-treat complications of surgery. severe postoperative pain can significantly impair patients' quality of life, social functioning and contribute to excessive health care expenditures. It is worth noting that acute postoperative pain may play a vital role in central sensitization and up-regulation of pain receptors, even factors implicated in the development of CPSP. According to previous studies, the incidence of postoperative pain among patients undergoing spinal surgery was nearly 80%. At the same time, perioperative pain management of patients undergoing spinal surgery has not been clearly. For the past few years, pregabalin and esketamine are becoming important roles in perioperative pain management, lots of studies have shown that these two analgesics might relieve postoperative pain. The aim of this study was to evaluate the acute analgesic effects of esketamine and pregabalin in combination after spinal cord neoplasms resection, so as to find a better way to help the patients undergoing spinal surgery keep away from the acute perioperative pain.

Interventions

* Drug: Pregabalin * 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14) * Drug: S-ketamine infusion * 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h

* Drug: Placebo capsules * Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days * Drug: Normal saline * 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours

Sponsors

Beijing Tiantan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patient undergoing elective spinal cord neoplasms resection; * Ages between 18 and 65 years old; * American Society of Anaesthesiology (ASA) status I-III; * Signed informed consent.

Exclusion criteria

* Previous adverse reaction to ketamine, s-ketamine or pregabalin; * Patients with a diagnosed history of severe chronic pain; * Patients with long-term analgesic treatment(gabapentin/opioids/ketamine); * Patients with aphasia or inability to cooperate with the pain assessments; * Known sever insufficiency of vitals(such as heart failure/renal dysfunction/hepatic failure); * Patients with a diagnosed history of psychiatric disorder; * Patients treated with gabapentin/pregabalin in the last three months; * Drug abuse; * Body mass index (BMI) \> 35 kg/m2 ; * Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frameDescription
the proportion of patients with acute moderate-to-severe postsurgical pain during 48h after operation48 hours after operationThe primary outcome was the proportion of patients with acute moderate-to-severe postsurgical pain during the 48-h postoperative period (defined as a VAS score ≥ 40 mm).

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026